Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Bausch Health Companies Inc (NYSE: BHC) closed the day trading at $7.45 down -0.67% from the previous closing price of $7.5. In other words, the price has decreased by -$0.67 from its previous closing price. On the day, 1.3 million shares were traded. BHC stock price reached its highest trading level at $7.73 during the session, while it also had its lowest trading level at $7.425.
Ratios:
For a better understanding of BHC, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.64. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 1.30.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $8.
On August 02, 2024, Piper Sandler Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $9 to $3.
On July 10, 2024, Raymond James started tracking the stock assigning a Mkt Perform rating and target price of $8.Raymond James initiated its Mkt Perform rating on July 10, 2024, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’25 when PAULSON & CO. INC. bought 2,500,000 shares for $6.25 per share. The transaction valued at 15,625,000 led to the insider holds 73,255,869 shares of the business.
Carson Seana sold 13,370 shares of BHC for $97,735 on Sep 08 ’25. The EVP, General Counsel now owns 499,585 shares after completing the transaction at $7.31 per share. On Sep 08 ’25, another insider, Carson Seana, who serves as the Officer of the company, bought 13,370 shares for $7.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BHC now has a Market Capitalization of 2763575296 and an Enterprise Value of 23415351296. As of this moment, Bausch’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.69, and their Forward P/E ratio for the next fiscal year is 1.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.28. Its current Enterprise Value per Revenue stands at 2.335 whereas that against EBITDA is 7.126.
Stock Price History:
The Beta on a monthly basis for BHC is 0.42, which has changed by -0.019607842 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, BHC has reached a high of $8.69, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is 8.38%, while the 200-Day Moving Average is calculated to be 19.08%.
Shares Statistics:
Over the past 3-months, BHC traded about 2.52M shares per day on average, while over the past 10 days, BHC traded about 1847770 shares per day. A total of 370.47M shares are outstanding, with a floating share count of 328.12M. Insiders hold about 11.44% of the company’s shares, while institutions hold 65.01% stake in the company. Shares short for BHC as of 1767139200 were 4835516 with a Short Ratio of 1.92, compared to 1764288000 on 5649348. Therefore, it implies a Short% of Shares Outstanding of 4835516 and a Short% of Float of 1.4099999.
Earnings Estimates
The performance of Bausch Health Companies Inc (BHC) in the stock market is under the watchful eye of 6.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.7, with high estimates of $0.84 and low estimates of $0.51.
Analysts are recommending an EPS of between $4.02 and $3.72 for the fiscal current year, implying an average EPS of $3.91. EPS for the following year is $4.2, with 6.0 analysts recommending between $4.66 and $3.72.
Revenue Estimates
6 analysts predict $2.71B in revenue. The current quarter. It ranges from a high estimate of $2.76B to a low estimate of $2.66B. As of. The current estimate, Bausch Health Companies Inc’s year-ago sales were $2.56BFor the next quarter, 6 analysts are estimating revenue of $2.42B. There is a high estimate of $2.44B for the next quarter, whereas the lowest estimate is $2.41B.
A total of 6 analysts have provided revenue estimates for BHC’s current fiscal year. The highest revenue estimate was $10.23B, while the lowest revenue estimate was $10.13B, resulting in an average revenue estimate of $10.18B. In the same quarter a year ago, actual revenue was $9.62BBased on 6 analysts’ estimates, the company’s revenue will be $10.52B in the next fiscal year. The high estimate is $10.77B and the low estimate is $10.08B.
